艾力斯创新药品伏美替尼、戈来雷塞纳入新版国家医保目录

Core Viewpoint - Elysium (688578) announced that its innovative drugs, Fumetidine (brand name "Aifusha") and Goleirese (brand name "Airikai"), have been included in the National Medical Insurance Directory for 2025, enhancing their market accessibility and potential sales growth [1] Group 1 - Fumetidine has been retained in the National Medical Insurance Directory for first-line and second-line treatment indications after successful negotiations [1] - Goleirese has been included in the National Medical Insurance Directory for second-line treatment indications for the first time through negotiation [1]